Thursday, 17 Oct 2019

You are here

Intraarticular Capsaicin in Knee Osteoarthritis

A novel compound, synthetic trans‐capsaicin (CNTX‐4975), has been studied as an intraarticular injection and shown to significantly reduce pain in patients with chronic moderate‐to‐severe osteoarthritis (OA) of the knee.

A phase II, multicenter, double‐blind study enrolled 172 knee OA patients between the ages of 45–80 years. Patients were randomized to receive either intraarticular placebo, or a high‐purity synthetic trans‐capsaicin CNTX‐4975 0.5 mg, or CNTX‐4975 1.0 mg. 

A single intraarticular injection (4 ml) of placebo, CNTX‐4975 0.5 mg, or CNTX‐4975 1.0 mg was administered. Premedication with opioid, NSAID, or topical anesthetic (e.g., ethyl chloride, topical or subcutaneous lidocaine), and joint cooling before and after the study injection was permitted. 

The primary efficacy end point of the study was improvement in pain as measured by the under the curve (AUC) for change from baseline in daily Western Ontario and McMaster Universities Osteoarthritis (WOMAC) pain Index. 

Week 12 results showed superiority for CNTX‐4975 over PBO:

  • CNTX-4875 0.5 mg vs PBO for least squares mean difference [LSMD] −0.79, P = 0.0740;
  • CNTX-4875 1.0 mg vs PBO LSMD −1.6, P < 0.0001.
  • Significant improvements were maintained at week 24 in the 1.0 mg group (LSMD −1.4, P = 0.0002).

Whereas the CNTX-4875 1mg group maintained its lower pain scores (LSMD −1.4; P < 0.001) out to week 24, the CNTX-4875 0.5 mg group lost its pain  efficacy after week 12 (LSMD −0.6; P = 0.19). 

Acetaminophen use (13,392 mg vs. 21,006mg) and ibuprofen use (7445 mg vs. 9304 mg) at 12 weeks was also significantly less in the intraaritular CNTx-4875 patints compate to placebo treated patients.  

Treatment‐emergent adverse events were mild, nonspecific and not significantly dissimilar between groups. 

CNTX‐4975 provided dose‐dependent improvement in knee OA–associated pain for 12 to 24 weeks, depending on the dose.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Sprifermin Benefits Cartilage Loss but not Symptoms in Knee Osteoarthritis

Intra-articular sprifermin given to patients with symptomatic and radiographic knee osteoarthritis has been shown to significantly improve total femorotibial joint cartilage thickness after 2 years, but without significant clinical benefits. Which begs the question, why is there a disconnect between radiographic disease modification (cartilage thickness) and symptomatic improvement?

Bisphosphonates and the Risk of Osteonecrosis of the Jaw

Even though oral bisphosphonates are widely used, there is an inordinate concern over the risk of osteonecrosis of the jaw (ONJ). A new UK study suggests that the risk of ONJ is elevated six fold by the use of biphosphonates.

ASBMR Recommendations on Secondary Fracture Prevention

The American Society for Bone and Mineral Research has developed multistakeholder consensus clinical recommendations for the prevention of secondary fractures for those aged 65 years and older after an initial hip or vertebral fracture.

Overall they have promoted 13 recommendations (7 primary and 6 secondary) strongly supported medical evidence.

Highlights include recommendations for:

Similar Outcomes for Hip Arthroplasty or Hemiarthroplasty in Hip Fracture

The NEJM reports on a randomized comparison of hemiarthroplasty and total hip arthroplasty in displaced femoral neck fractures and shows no difference in function and quality of life over 24 months.

Need for Pre-operative Hyperglycemia Testing Prior to Total Joint Replacement

JAMA reports on a large Medicare cohort study showing that amongst patients undergoing total joint replacement (TJR), preoperative HbA1c testing was performed in 26% to 43% of patients with diabetes and in only 5% of those without diabetes. Importantly research has shown that an elevated HbA1c level is associated with postoperative complications.